How Treatable Is Stage 3 Lung Cancer?

For some patients, treatment can still be given with the intention of curing the cancer.

The difficulty is that stage 3 covers a wide range of situations. The cancer may have spread to nearby lymph nodes or structures within the chest, and the extent of that spread can differ considerably between patients. Treatment therefore depends on the precise stage, type of lung cancer, tumour characteristics and whether the patient is well enough for the treatments being considered.

What Does Stage 3 Lung Cancer Mean?

Stage 3 lung cancer is generally described as locally advanced disease. The cancer has spread more extensively within the chest but has not spread to distant organs.

For non-small cell lung cancer (NSCLC), stage 3 is further divided into stages IIIA, IIIB and IIIC. These categories reflect differences in the size or extent of the tumour and which lymph nodes or nearby structures are involved.

Some stage IIIA cancers may be considered for surgery as part of a broader treatment approach, while many stage 3 cancers are not suitable for surgical removal and are treated using combinations of chemotherapy, radiotherapy and, where appropriate, immunotherapy.

This is why an individual lung cancer treatment plan needs to be based on accurate staging rather than the words "stage 3" alone.

Can Stage 3 Lung Cancer Be Treated With Curative Intent?

Yes. Selected patients with stage 3 lung cancer can receive treatment with curative intent.

This differs from stage 4 lung cancer, where the disease has spread to distant parts of the body and treatment is more often focused on controlling the cancer, prolonging life and maintaining quality of life.

For locally advanced NSCLC that cannot be removed surgically, concurrent chemoradiotherapy is an established treatment approach for patients who are suitable for it. Chemotherapy and radiotherapy are given during the same treatment period, allowing the treatments to work together against the cancer.

For eligible patients whose disease has not progressed following concurrent platinum-based chemoradiotherapy, consolidation immunotherapy may then be considered.

The possibility of cure does not mean that treatment will be successful for every patient. Stage 3 remains a challenging cancer to treat, and recurrence can occur. However, it is inaccurate to assume that reaching stage 3 automatically removes the possibility of curative treatment.

What treatment success means can also vary between patients. Questions about lung cancer remission rates and treatment outcomes therefore need to be considered in the context of the precise stage, tumour biology and treatment being used.

Why Chemotherapy and Radiotherapy Are Often Combined

Stage 3 disease frequently requires treatment that addresses both the tumour within the chest and areas of cancer involvement such as regional lymph nodes.

Chemoradiotherapy for lung cancer combines two treatment approaches. Radiotherapy targets the cancer within the treatment area, while chemotherapy acts systemically and can also make cancer cells more sensitive to radiation.

When clinically appropriate, the treatments may be delivered concurrently rather than one after the other. The chemotherapy helps the radiotherapy to work.

Modern radiotherapy is carefully planned around the tumour and areas requiring treatment while limiting radiation exposure to surrounding healthy tissues as far as possible.

This can still be intensive treatment. Potential side effects depend on the chemotherapy drugs and the area receiving radiation, but may include fatigue, difficulty or discomfort when swallowing, nausea, changes in blood counts and inflammation of the lungs.

Treatment planning therefore needs to balance the intensity required to control the cancer with what can be delivered safely.

Does Everyone With Stage 3 Lung Cancer Receive the Same Treatment?

No. Two people with stage 3 lung cancer can have quite different treatment plans.

The recommendation may be influenced by:

• Whether the cancer is NSCLC or small cell lung cancer
• Whether it is stage IIIA, IIIB or IIIC
• Which lymph nodes and nearby structures are involved
• Whether surgery is technically possible and appropriate
• Lung and heart function
• General health and fitness
• Tumour pathology and relevant biomarkers
• Previous medical conditions and treatments
• The presence or absence of target or gene mutations in the cancer

Selected patients with potentially resectable stage III NSCLC may have surgery incorporated into multimodality treatment. Others may receive definitive chemoradiotherapy.

Small cell lung cancer is staged and managed somewhat differently, although limited-stage disease may also be treated with chemotherapy and thoracic radiotherapy.

The term "stage 3" therefore provides important information, but it does not by itself tell you exactly what treatment you will receive.

What Happens After Chemoradiotherapy?

For some patients with unresectable stage 3 NSCLC, treatment does not necessarily finish when chemoradiotherapy ends.

For eligible patients whose disease has not progressed following concurrent platinum-based chemoradiotherapy, consolidation immunotherapy with durvalumab may be considered. In England, current NICE guidance recommends durvalumab as an option for locally advanced unresectable NSCLC with PD-L1 expression on 1% or more of tumour cells when the disease has not progressed following concurrent platinum-based chemoradiotherapy.

Immunotherapy in cancer treatment works differently from chemotherapy by helping the immune system recognise and attack cancer cells. Its role varies according to the cancer type, stage, biomarkers and treatment setting, and not every patient will be suitable for the same approach.

Follow-up imaging is also important. Scans help assess the response to treatment and monitor for recurrence or progression.

Changes seen on scans after thoracic radiotherapy are not always straightforward  to interpret. Radiation can produce inflammation and later scarring within the lung, so imaging needs to be interpreted in the context of the treatment received and how the findings change over time.

Following the results of the LAURA clinical trial, patients with EGFR-mutated non-small cell lung cancer will receive osimertinib after completing chemotherapy, rather than immunotherapy.

What Affects the Outlook for Stage 3 Lung Cancer?

There is no single prognosis that applies to everyone with stage 3 disease.

Stage IIIA, IIIB and IIIC do not carry identical outlooks, and prognosis can also vary according to the lung cancer subtype, lymph-node involvement, tumour biology, response to treatment and general health.

Whether treatment can be delivered with curative intent is another important consideration.

This is why survival statistics need to be interpreted carefully. Population figures describe outcomes across groups of patients and cannot predict exactly what will happen to an individual.

The broader picture of locally advanced lung cancer therefore includes not only the stage itself but also whether the cancer is resectable, the treatment that can safely be delivered and how the disease responds.

Can Exercise Help During Stage 3 Lung Cancer Treatment?

Exercise does not treat the cancer itself, but maintaining physical function can be an important part of supportive care before, during and after treatment.

Stage 3 treatment can be demanding, particularly when chemotherapy and radiotherapy are given together. Fatigue, reduced activity, breathlessness and loss of strength can make normal daily activities more difficult.

Appropriately tailored exercise for lung cancer patients may help support physical function and manage treatment-related problems such as fatigue. The appropriate level of activity depends on fitness, symptoms, other medical conditions and the treatment being received.

For someone undergoing intensive cancer treatment, exercise should therefore be adapted to the individual rather than approached as a generic fitness programme.

What If Stage 3 Lung Cancer Cannot Be Treated With Concurrent Chemoradiotherapy?

Not everyone is able to receive concurrent chemoradiotherapy.

The cancer's extent may make a particular radiotherapy approach unsuitable, or other health conditions may mean that intensive combined treatment carries too much risk. In some cases, chemotherapy and radiotherapy may be delivered sequentially rather than concurrently.

Other treatment strategies may also be considered depending on the cancer subtype, molecular findings, general health and overall aims of treatment.

Being unable to receive one particular treatment does not necessarily mean there are no other options. It means the balance between potential benefit and treatment risk needs to be considered differently.

When a Second Opinion May Be Helpful

Stage 3 lung cancer is one of the situations where treatment planning can become particularly complex because several specialities and treatment approaches may be involved.

A reputable consultant oncologist can help provide greater clarity around how existing scan results, pathology and staging relate to the treatment options being considered.

A second opinion may also be useful if you are uncertain why a particular treatment has been recommended, have been given different options or want an independent review before beginning a major course of treatment.

The aim is not necessarily to find a completely different recommendation. Sometimes another review confirms that the existing plan is appropriate while helping you understand more clearly why it has been chosen.

How Treatable Is Stage 3 Lung Cancer Overall?

Stage 3 lung cancer is challenging to treat, but locally advanced does not mean untreatable.

For selected patients, treatment can still be delivered with curative intent. Chemoradiotherapy remains an important treatment for unresectable locally advanced NSCLC, while consolidation immunotherapy has improved outcomes for eligible patients. Surgery can also have a role in carefully selected stage 3 cases.

What matters is establishing precisely what type of stage 3 disease is present, its extent within the chest and which treatment approach offers an appropriate balance of effectiveness and safety.

Accurate staging, pathology and individual treatment planning are therefore particularly important at this stage.

About Dr James Wilson

Stage 3 lung cancer can require several treatments to work together, and the most appropriate approach depends on much more than the stage number alone. Cancer subtype, lymph node involvement, overall health, and suitability for different treatments all contribute to the decision.

Dr James Wilson is a consultant clinical oncologist in full-time private practice in Central London, specialising in lung cancer and advanced radiotherapy. His approach is centred on clear, consultant-led care, helping patients understand their treatment options and access specialist advice promptly, without unnecessary delays.